Success Stories: A Nigerian Research Fellow in Biotechnologies Wins NIW Approval in Just 4 Months, Thanks to Our Team’s Efforts with Her Case

Client’s Testimonial:

“I am reaching out to say a big thank you for your effort and guidance toward my application.”

On February 15^th, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Research Fellow in the Field of Biotechnologies (Approval Notice).

General Field: Biotechnologies

Position at the Time of Case Filing: Research Fellow

Country of Origin: Nigeria

State of Residence at the Time of Filing: Minnesota

Approval Notice Date: February 15^th, 2023

Processing Time: 4 months, 4 days

Case Summary:

When a client from Nigeria wanted to file her National Interest Waiver petition with our help, our team first made sure that she was aware of the requirements and then proceeded to sign the retainer agreement with her. Once these formalities were over, we began collecting her documents and found the following information in them:

As an expert in the field of biotechnologies, her proposed research is on deciphering genomic information as well as developing and applying advanced biotechnological research. She wanted to help progress medical research and health care by pinpointing early diagnostic genetic biomarkers or pathobionts that are significant factors in disease development. This would assist in developing preventative treatments that intervene before the materialization and progression of the disease.
Her research endeavor is of great importance because it addresses the biomolecular roots of certain medical issues and offers practical applications to reduce them on a global scale. For instance, she has investigated the major difference observed between rates of PTB among women from different areas of the world.
Her work also has broad implications for the United States since her endeavor to decipher genomic information and develop methods to progress PTB research and healthcare involves providing the scientific community with novel information about the interrelationship of PTB, hormone concentration, and vaginal microbiome composition, which is practicable in terms of treating PTB and reducing its burden in the United States.
Due to its clear national importance, her research has in fact been supported with funding from the U.S. Department of Agriculture (USDA), National Science Foundation (NSF), National Institute of Health (NIH), and National Center for Advancing Translational Science (NCATS).
In the 4 years of her research, she has completed at least 10 reviews and her work has been published in 7 peer-reviewed journal articles (4 of them first-authored) which have been cited a total of 24 times according to Google Scholar.
Not only this but her work’s value has also been identified by other experts in the field, 4 of whom sent letters recommending her work. One of them wrote:

“Due to her background in veterinary science and experience with molecular microbiology, reproductive biology, multi-omics, virology, metagenomics, and more, [the client] brings a truly unique perspective to the field. As a powerful voice, she provides critical, novel insights into the role of genetics, biology, and cellular and microbial changes in disease. Her continued research in America is sure to significantly advance preventative medicine and novel, personalized pharmaceutical and therapeutic interventions.”

So, when the filing was complete we waited patiently for the results. Our efforts were soon answered when we got the approval without an RFE in just 4 months and 4 days. We are very proud of this success and our firm wishes the client an amazing future ahead.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.